Dare Bioscience, Inc. Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
Dare Bioscience, Inc. (DARE) reported Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross of $5.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross · last filed 2026-03-26
- Dare Bioscience, Inc. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2024 was $5.00M.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 12 month |
|---|---|
| 2024-12-31 | $5.00M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |